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           Introduction: In healthy postmenopausal women increased platelet activation has been 
associated with the adverse cardiovascular events including unstable angina, myocardial 
infarction, stroke and other thrombotic states. There is much debate about the relationship 
between platelet function and serum estradiol levels in such postmenopausal women. It is 
postulated that estrogen may result in decreased platelet activation. 
 
Objectives: The aim of the study was to determine the effect of HRT on the platelet 
activation markers (CD62P & PAC-1) in healthy postmenopausal women and to determine the 
correlation between platelet activation markers and serum estradiol, BMI and Age of 
postmenopausal women.  
 
            Patients and Methods: A prospective case control study on 48 postmenopausal women 
was conducted at Hospital Universiti Sains Malaysia (HUSM). Group-A consisted of 48 women 
NOT on HRT (Control Group) and Group-B comprised of same 48 women who were given HRT 
(Conjugated equine estrogen 0.625 mg orally once daily) for two weeks (Study group). Platelet 
activation was evaluated at baseline and after two weeks of treatment by flow cytometric 
analysis using CD62P and PAC1 as activation markers. Comparisons within groups (before and 
after HRT) were analyzed using the paired t-tests.  
 
             Results: The expressions of CD62P and PAC1 showed a decreased platelet activation 
status in postmenopausal women who were given HRT. Platelet activation markers (CD62P & 
PAC-1) among healthy postmenopausal women in the group-A were 7.00% ±5.91 (CD62P) and 
41.75% ±26.85(PAC-1) respectively (increased platelet activation in this group) which were 
reduced to 3.05% ±2.47 (CD62P) and 20.86% ±19.02 (PAC-1) respectively in the group-B after 
two weeks of HRT administration (p-value <0.001). 
 
          Conclusion: HRT decreases the platelet activation markers (CD62P & PAC-1) in healthy 
post menopausal women. Platelet activation markers (CD62P & PAC-1) are found to be 
increased in healthy postmenopausal women as compared to the postmenopausal women who 
were treated with HRT. There is a significant negative fair correlation between estradiol and 
platelet activation markers (CD62P & PAC-1) however; there was no significant relation among 
BMI, age and platelet activation markers.  
It is concluded that short term use of HRT has a favorable effect on reduction of platelet activity 
in post-menopausal women and thus it is postulated to be cardio protective. Further study on the 
long term effect of HRT on platelets is needed. 
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ABSTRACT 
 
A STUDY TO INVESTIGATE THE EFFECT OF HORMONE REPLACEMENT 
THERAPY (HRT) ON PLATELET ACTIVATION MARKERS (CD62P & PAC-1) 
DETERMINED BY FLOW CYTOMETRY IN HEALTHY POSTMENOPAUSAL 
WOMEN. 
 
Objectives:  
The aim of the study was to determine the effect of HRT on the platelet activation markers 
(CD62P & PAC-1) in healthy postmenopausal women. In such women platelet activation has 
been associated with the adverse cardiovascular events including unstable angina, myocardial 
infarction, stroke and other thrombotic states. There is much debate about the relationship 
between platelet function and serum estradiol levels including concerns about the influence of 
low estradiol in menopausal women. It is postulated that estrogen may result in decreased 
platelet activation. 
Methodology:  
A prospective case control study on 48 postmenopausal women was conducted at Hospital 
USM. Group-A consisted of 48 women NOT on HRT (Control Group) and Group-B 
comprised of same 48 women who were given HRT (Conjugated equine estrogen 0.625 mg 
orally once daily) for two weeks (Study group). Platelet activation was evaluated at baseline 
and after two weeks of treatment by flow cytometric analysis using CD62P and PAC1 as 
activation markers. Comparisons within groups (before and after HRT) were analyzed using 
the paired t-tests.  
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Results:  
The expressions of CD62P and PAC1 showed a decreased platelet activation status in 
postmenopausal women who were given HRT. Platelet activation markers (CD62P & PAC-1) 
among healthy postmenopausal women in the group-A were 7.00% ±5.91 (CD62P) and 
41.75% ±26.85(PAC-1) respectively (increased platelet activation in this group) which were 
reduced to 3.05% ±2.47 (CD62P) and 20.86% ±19.02 (PAC-1) respectively in the group-B 
after two weeks of HRT administration (p-value <0.001). 
 Conclusion:  
HRT decreases the platelet activation markers (CD62P & PAC-1) in healthy post menopausal 
women. Platelet activation markers (CD62P & PAC-1) are found to be increased in healthy 
postmenopausal women as compared to the postmenopausal women who were treated with 
HRT. There is a significant negative fair correlation between estradiol and platelet activation 
markers (CD62P & PAC-1) however; there was no significant relation among BMI, age and 
platelet activation markers.  
It is concluded that short term use of HRT has a favorable effect on reduction of platelet 
activity in post-menopausal women and thus it is postulated to be cardio protective. Further 
study on the long term effect of HRT on platelets is needed. 
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ABSTRAK 
 
KAJIAN UNTUK MENGENAL PASTI KESAN TERAPI HORMON KEATAS 
PETANDA (MARKERS) AKTIVASI PLATELET MELALUI KAEDAH “FLOW 
CYTOMETRY” KEATAS WANITA PUTUS HAID YANG SIHAT. 
 
Objektif:  
Tujuan kajian ini adalah untuk menentukan kesan terapi hormon terhadap petanda aktivasi 
platelet di kalangan wanita yang telah putus haid. Ini kerana aktiviti pengaktifan platelet  
dikaitkan dengan kesan negatif terhadap kardiovaskular termasuk ketidakstabilan angina, 
sakit jantung, angin ahmar dan pembekuan saluran darah. Terdapat banyak kontroversi 
berkaitan dengan fungsi platelet dan tahap serum estradiol termasuk pengaruh serum estradiol 
yang rendah dikalangan wanita yang telah putus haid. Ramai yang berpendapat oestrogen 
mungkin mengurangkan fungsi pengaktifan platelet.  
Kaedah:  
Kajian secara prospektif kontrol telah dijalankan melibatkan 48 wanita yang telah putus haid 
di Hospital USM. Kumpulan A merangkumi 48 peserta yang tidak diberikan terapi hormon 
(kumpulan control) dan Kumpulan B melibatkan 48 orang peserta yang sama yang diberikan 
terapi hormon (Conjugated equine estrogen 0.625mg-satu kali sehari) untuk 2 minggu 
(Kumpulan Kajian). Pengaktifan platelet telah dianalisa pada permulaan kajian dan selepas 2 
minggu rawatan menggunakan terapi hormon dengan menggunakan kaedah “flowcytometry” 
untuk CD62P dan PAC1 sebagai pengaktifan markers. Perbandingan diantara kumpulan 
(sebelum dan selepas terapi hormon) dianalisa menggunakan ujian-t.  
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Keputusan:  
Penghasilan CD62P dan PAC1 menunjukan pengurangan status pengaktifan platelet di 
kalangan wanita yang telah putus haid yang telah diberikan terapi hormon. CD62P dan PAC1 
dikalangan wanita yang telah putus haid pada kumpulan kontrol telah mengurang secara 
signifikan dari 7.00% ±5.91 kepada 3.05% ±2.47 dan 41.75%  ± 26.85  kepada 20.86% 
±19.02  selepas diberikan terapi hormon (kadar-p < 0.001).  
Kesimpulan: 
 Terapi hormon menurunkan petanda aktivasi platelet (CD62P & PAC1) di kalangan wanita 
sihat yang telah putus haid. Petanda aktivasi platelet (CD62P & PAC1) meningkat di 
kalangan wanita putus haid yang sihat berbanding dengan wanita yang telah putus haid yang 
diberikan terapi hormon. Terdapat “korelasi signifikan secara negatif” diantara estradiol dan 
petanda aktivasi platelet, walau bagaimanapun tidak terdapat kaitan yang signifikan terhadap 
indeks isipadu tubuh (BMI), umur dan petanda aktivasi platelet.  
Kesimpulannya, penggunaan terapi hormon secara sementara memberikan kesan positif 
terhadap pengurangan aktiviti platelet di kalangan wanita yang telah putus haid dan ini 
mungkin memberikan kesan positif terhadap kardiovascular. Kajian yang lebih lanjut 
diperlukan untuk menentukan kesan jangka panjang terapi hormon terhadap platelet.  
 
 
